

Product Datasheet

GLS2 Antibody - BSA Free NBP1-76544

Unit Size: 0.1 mg

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

www.novusbio.com



technical@novusbio.com

Publications: 8

Protocols, Publications, Related Products, Reviews, Research Tools and Images at:
www.novusbio.com/NBP1-76544

Updated 4/13/2025 v.20.1

Earn rewards for product
reviews and publications.

Submit a publication at www.novusbio.com/publications

Submit a review at www.novusbio.com/reviews/destination/NBP1-76544



NBP1-76544


GLS2 Antibody - BSA Free

Product Information	
Unit Size	0.1 mg
Concentration	1 mg/ml
Storage	Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Clonality	Polyclonal
Preservative	0.02% Sodium Azide
Isotype	IgG
Purity	Immunogen affinity purified
Buffer	PBS
Target Molecular Weight	66 kDa
Product Description	
Host	Rabbit
Gene ID	27165
Gene Symbol	GLS2
Species	Human, Mouse, Rat
Reactivity Notes	Use in Human reported in scientific literature (PMID:33799686).
Specificity/Sensitivity	Specificity for GLS2 versus GLS1 has not been determined.
Immunogen	Antibody was raised against a 18 amino acid peptide near the center terminus of human GLS2 (NP_037399).
Product Application Details	
Applications	Western Blot, Simple Western, ELISA, Immunocytochemistry/Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Paraffin
Recommended Dilutions	Western Blot 0.5-1 ug/ml, Simple Western 1:100, ELISA 1:100-1:2000, Immunohistochemistry 5 ug/ml, Immunocytochemistry/ Immunofluorescence 20 ug/mL, Immunohistochemistry-Paraffin 5 ug/ml
Application Notes	In Simple Western only 10 - 15 uL of the recommended dilution is used per data point. See Simple Western Antibody Database for Simple Western validation: Tested in Hek293 lysate 0.5 mg/mL, separated by Size, antibody dilution of 1:100, apparent MW was 60 kDa. Separated by Size-Wes, Sally Sue/Peggy Sue. The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.




Images


Western Blot: GLS2 Antibody [NBP1-76544] - Glutaminase protein expression in PC3 and PC3M cell lines before/after CB-839 treatment. PC3 & PC3M cells were treated (+) or not treated (-) with GLS1 inhibitor CB-839 (1 μ M) and their expression of GLS1 & GLS2 proteins determined by Western blot. Antibodies specific for GAC & KCA were utilized on two replicate samples, while GLS2 expression was determined on three. PC3 cell lysates expressed GLS2 more than PC3M cell lysates regardless of CB-839 treatment. The difference in GLS2 expression was significant in the untreated cells ($P < 0.03$) but because of high variability the difference was not significant in the drug-treated cells. Levels of GLS1 (GAC and KCA) were similar in all cell lysates. Image collected and cropped by CiteAb from the following publication (<https://www.nature.com/articles/s41598-017-16327-z>), licensed under a CC-BY license.




Immunocytochemistry/Immunofluorescence: GLS2 Antibody [NBP1-76544] - of GLS2 in Human Kidney cells. Dilution 20 μ g/mL.




Immunohistochemistry: GLS2 Antibody [NBP1-76544] - Immunohistochemistry of GLS2 in human kidney tissue with GLS2 antibody at 5 μ g/mL.



Simple Western: GLS2 Antibody [NBP1-76544] - Simple Western lane view shows a specific band for GLS2 in 0.5 mg/ml of Hek293 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.



Immunocytochemistry/ Immunofluorescence: GLS2 Antibody - BSA Free [NBP1-76544] - Histological analyses for assessing response to bevacizumab treatment. A Immunofluorescence staining of tumor vasculature & integrin $\beta 3$ with antibodies against CD31 (green) & CD61 (integrin $\beta 3$, red) in the treated & control groups at the end of the study. B Quantitative analysis of integrin $\beta 3$ & CD31-positive area fraction of tumors between the control & treatment groups. $**P < 0.05$. Magnification: $\times 200$. Microvascular density (CD31) from the therapy group (C) & control group (D). Tumor cell proliferation (Ki-67) from the therapy group (F) & control group (G). Quantitative MVD (E) & Ki67 (H) assessment of therapy & control group. Error bars denote standard errors, Mann–Whitney U-test were applied, $**P < 0.05$. Magnification: $\times 200$ Image collected & cropped by CiteAb from the following publication (<https://pubmed.ncbi.nlm.nih.gov/31604441>), licensed under a CC-BY license. Not internally tested by Novus Biologicals.



Publications

Cavino K, Sung B, Su Q, Na E et al. Glucagon Receptor Inhibition Reduces Hyperammonemia and Lethality in Male Mice with Urea Cycle Disorder *Endocrinology* 2020-11-18 [PMID: 33206168]

Emmanuel Benichou, Bolaji Seffou, Selin Topçu, Ophélie Renoult, Véronique Lenoir, Julien Planchais, Caroline Bonner, Catherine Postic, Carina Prip-Buus, Claire Pecqueur, Sandra Guilmeau, Marie-Clotilde Alves-Guerra, Renaud Dentin The transcription factor ChREBP Orchestrates liver carcinogenesis by coordinating the PI3K/AKT signaling and cancer metabolism *Nature Communications* 2024-02-29 [PMID: 38424041]

Arenas YM, Felipo V Sustained Hyperammonemia Activates NF- κ B in Purkinje Neurons Through Activation of the TrkB-PI3K-AKT Pathway by Microglia-Derived BDNF in a Rat Model of Minimal Hepatic Encephalopathy *Molecular neurobiology* 2023-02-15 [PMID: 36790604] (Western Blot)

Mao X, Chen H, Lin A et al. Glutaminase 2 Knockdown Reduces Hyperammonemia and Associated Lethality of Urea Cycle Disorder Mouse Model *Journal of inherited metabolic disease* 2022-01-06 [PMID: 34988999] (WB, Mouse)

Zacharias N, Wang L, Maity T et al. Prolyl Hydroxylase 3 Knockdown Accelerates VHL-Mutant Kidney Cancer Growth In Vivo *International Journal of Molecular Sciences* 2021-03-11 [PMID: 33799686] (WB, Human)

Wang Y, Liu H, Yao D et al. 18F-labeled magnetic nanoparticles for monitoring anti-angiogenic therapeutic effects in breast cancer xenografts *J Nanobiotechnology* 2019-10-11 [PMID: 31604441] (IHC-P, Mouse)

Zacharias NM, McCullough C, Shanmugavelandy S et al. Metabolic Differences in Glutamine Utilization Lead to Metabolic Vulnerabilities in Prostate Cancer *Sci Rep.* 2017-11-23 [PMID: 29170516] (WB, Human)

Gross MI, Demo SD, Dennison JB et al. Antitumor Activity of the Glutaminase Inhibitor CB-839 in Triple-Negative Breast Cancer. *Mol. Cancer Ther.* 2014-02-13 [PMID: 24523301] (WB, Human)



Novus Biologicals USA

10730 E. Briarwood Avenue
Centennial, CO 80112
USA
Phone: 303.730.1950
Toll Free: 1.888.506.6887
Fax: 303.730.1966
nb-customerservice@bio-techne.com

Bio-Techne Canada

21 Canmotor Ave
Toronto, ON M8Z 4E6
Canada
Phone: 905.827.6400
Toll Free: 855.668.8722
Fax: 905.827.6402
canada.inquires@bio-techne.com

Bio-Techne Ltd

19 Barton Lane
Abingdon Science Park
Abingdon, OX14 3NB, United Kingdom
Phone: (44) (0) 1235 529449
Free Phone: 0800 37 34 15
Fax: (44) (0) 1235 533420
info.EMEA@bio-techne.com

General Contact Information

www.novusbio.com
Technical Support: nb-technical@bio-techne.com
Orders: nb-customerservice@bio-techne.com
General: novus@novusbio.com

Products Related to NBP1-76544

NBP1-76544PEP-0.1mg	GLS2 Antibody Blocking Peptide
HAF008	Goat anti-Rabbit IgG Secondary Antibody [HRP]
NB7160	Goat anti-Rabbit IgG (H+L) Secondary Antibody [HRP]
NBP2-24891	Rabbit IgG Isotype Control

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

For more information on our 100% guarantee, please visit www.novusbio.com/guarantee

Earn gift cards/discounts by submitting a review: www.novusbio.com/reviews/submit/NBP1-76544

Earn gift cards/discounts by submitting a publication using this product:
www.novusbio.com/publications

